About US
Contact us
-
Innate Pharma acquires anti-C5aR antibody from Novo NordiskFrench biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m. The m2017/9/4
-
UK CMA accuses Merck of breaking competition law with discount schemeThe UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme(MSD) of operating an anti-competitive discount scheme for its medicine Remicade. Remicade2017/9/4
-
Novartis crosses FDA finish line with monumental CAR-T leukemia approvalIn a historic day for cancer treatment and the larger biopharma industry, Novartis notched an FDA approval for its CAR-T treatment tisagenlecleucel, a first-ever cell therapy for a rare form of acute2017/9/1
-
The Medicines Co. nets $400M nod for UTI antibacterial treatmentDoctors treating patients with complicated urinary tract infections will soon have a new tool in their arsenal with the FDA’s Tuesday approval for Vabomere, a combination of the antibacterial meropene2017/9/1
-
Shire disputes employee dissatisfaction report as UBS slashes price targetShire may have been plenty happy to finallylandlongtime buyout target Baxalta last year. But since then, its staffers haven’t been quite so pleased. Parsing 20,000 employee reviews from career websit2017/8/31
-
FDA blesses nonprofit-backed Chagas drug, thwarting ex-Shkreli biotech’s bid for rival launchMarking a dramatic step for a partnership aimingto affordably treat Chagas patients, the FDAapprovedthe group's antiparasitic treatment benznidazole. But the approval is an equally dramatic setbackfor2017/8/31
-
Sanofi veteran Peter Guenter exits top diabetes role to take helm at AlmirallSanofi’s loss is Almirall’s gain. The French drugmaker’s global diabetes and cardiovascular chief, Peter Guenter, has decamped for the top job at Almirall, a Spanish pharma that specializes in dermato2017/8/30
-
FDA refuses Acorda NDA for Parkinson's drug candidate because of manufacturing issuesWith generics threatening its main moneymaking medication, and an investor threatening its independence, Acorda Therapeutics has been pinning its hopes on approval of a new Parkinson’s disease drug. B2017/8/30
-
Havas Health quietly picks up Bristol-Myers Squibb's media business after Sanofi retention winThe new Havas Health & You is off to a solid start, especially considering the general downturn in the ad agency business for the first half of 2017. The business unit,createdin March by the combi2017/8/29
-
Novartis meeting, prior to CAR-T approval, leaves cancer patient concerned about pricingDavid Mitchell was pleasantly surprised when Novartis’ oncology chief, Bill Hinshaw, accepted his request for a meeting to discuss what a fair price might be for tisagenlecleucel (CTL019), its upcomin2017/8/29